Corpus
PascalFrancis
Racine
Corpus
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Impact of Belief in Neuroprotection on Therapeutic Intervention in Parkinson's Disease

Identifieur interne : 000A69 ( PascalFrancis/Corpus ); précédent : 000A68; suivant : 000A70

Impact of Belief in Neuroprotection on Therapeutic Intervention in Parkinson's Disease

Auteurs : Rodger J. Elble ; Oksana Suchowersky ; Stephanie Shaftman ; William J. Weiner ; PENG HUANG ; Barbara Tilley

Source :

RBID : Pascal:10-0314989

Descripteurs français

English descriptors

Abstract

We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double-blind placebo-controlled futility trial of coenzyme Q10 and GPI-1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  1    @0 0885-3185
A03   1    @0 Mov. disord.
A05       @2 25
A06       @2 8
A08 01  1  ENG  @1 Impact of Belief in Neuroprotection on Therapeutic Intervention in Parkinson's Disease
A11 01  1    @1 ELBLE (Rodger J.)
A11 02  1    @1 SUCHOWERSKY (Oksana)
A11 03  1    @1 SHAFTMAN (Stephanie)
A11 04  1    @1 WEINER (William J.)
A11 05  1    @1 PENG HUANG
A11 06  1    @1 TILLEY (Barbara)
A14 01      @1 Department of Neurology, Southern Illinois University School of Medicine @2 Springfield, Illinois @3 USA @Z 1 aut.
A14 02      @1 Department of Medical Genetics, University of Calgary @2 Calgary, Alberta @3 CAN @Z 2 aut.
A14 03      @1 Department of Clinical Neurosciences, University of Calgary @2 Calgary, Alberta @3 CAN @Z 3 aut.
A14 04      @1 Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina @2 Charleston, South Carolina @3 USA @Z 3 aut.
A14 05      @1 Department of Neurology, University of Maryland School of Medicine @2 Baltimore, Maryland @3 USA @Z 4 aut.
A14 06      @1 Department of Oncology, Johns Hopkins University @2 Baltimore, Maryland @3 USA @Z 5 aut.
A14 07      @1 Division of Biostatistics, University of Texas Health Science Center School of Public Health @2 Houston, Texas @3 USA @Z 6 aut.
A17 01  1    @1 NINDS NET-PD Investigators @3 INC
A20       @1 1082-1086
A21       @1 2010
A23 01      @0 ENG
A43 01      @1 INIST @2 20953 @5 354000170524820170
A44       @0 0000 @1 © 2010 INIST-CNRS. All rights reserved.
A45       @0 6 ref.
A47 01  1    @0 10-0314989
A60       @1 P @3 CC
A61       @0 A
A64 01  1    @0 Movement disorders
A66 01      @0 USA
C01 01    ENG  @0 We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double-blind placebo-controlled futility trial of coenzyme Q10 and GPI-1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment.
C02 01  X    @0 002B17
C02 02  X    @0 002B17G
C03 01  X  FRE  @0 Maladie de Parkinson @2 NM @5 01
C03 01  X  ENG  @0 Parkinson disease @2 NM @5 01
C03 01  X  SPA  @0 Parkinson enfermedad @2 NM @5 01
C03 02  X  FRE  @0 Pathologie du système nerveux @5 02
C03 02  X  ENG  @0 Nervous system diseases @5 02
C03 02  X  SPA  @0 Sistema nervioso patología @5 02
C03 03  X  FRE  @0 Croyance @5 09
C03 03  X  ENG  @0 Belief @5 09
C03 03  X  SPA  @0 Creencia @5 09
C03 04  X  FRE  @0 Traitement @5 10
C03 04  X  ENG  @0 Treatment @5 10
C03 04  X  SPA  @0 Tratamiento @5 10
C03 05  X  FRE  @0 Erreur systématique @5 11
C03 05  X  ENG  @0 Bias @5 11
C03 05  X  SPA  @0 Error sistemático @5 11
C03 06  X  FRE  @0 Essai clinique @5 12
C03 06  X  ENG  @0 Clinical trial @5 12
C03 06  X  SPA  @0 Ensayo clínico @5 12
C03 07  X  FRE  @0 Echelle d'évaluation @5 13
C03 07  X  ENG  @0 Evaluation scale @5 13
C03 07  X  SPA  @0 Escala evaluación @5 13
C07 01  X  FRE  @0 Pathologie de l'encéphale @5 37
C07 01  X  ENG  @0 Cerebral disorder @5 37
C07 01  X  SPA  @0 Encéfalo patología @5 37
C07 02  X  FRE  @0 Syndrome extrapyramidal @5 38
C07 02  X  ENG  @0 Extrapyramidal syndrome @5 38
C07 02  X  SPA  @0 Extrapiramidal síndrome @5 38
C07 03  X  FRE  @0 Maladie dégénérative @5 39
C07 03  X  ENG  @0 Degenerative disease @5 39
C07 03  X  SPA  @0 Enfermedad degenerativa @5 39
C07 04  X  FRE  @0 Pathologie du système nerveux central @5 40
C07 04  X  ENG  @0 Central nervous system disease @5 40
C07 04  X  SPA  @0 Sistema nervosio central patología @5 40
N21       @1 200
N44 01      @1 OTO
N82       @1 OTO

Format Inist (serveur)

NO : PASCAL 10-0314989 INIST
ET : Impact of Belief in Neuroprotection on Therapeutic Intervention in Parkinson's Disease
AU : ELBLE (Rodger J.); SUCHOWERSKY (Oksana); SHAFTMAN (Stephanie); WEINER (William J.); PENG HUANG; TILLEY (Barbara)
AF : Department of Neurology, Southern Illinois University School of Medicine/Springfield, Illinois/Etats-Unis (1 aut.); Department of Medical Genetics, University of Calgary/Calgary, Alberta/Canada (2 aut.); Department of Clinical Neurosciences, University of Calgary/Calgary, Alberta/Canada (3 aut.); Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina/Charleston, South Carolina/Etats-Unis (3 aut.); Department of Neurology, University of Maryland School of Medicine/Baltimore, Maryland/Etats-Unis (4 aut.); Department of Oncology, Johns Hopkins University/Baltimore, Maryland/Etats-Unis (5 aut.); Division of Biostatistics, University of Texas Health Science Center School of Public Health/Houston, Texas/Etats-Unis (6 aut.)
DT : Publication en série; Courte communication, note brève; Niveau analytique
SO : Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 8; Pp. 1082-1086; Bibl. 6 ref.
LA : Anglais
EA : We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double-blind placebo-controlled futility trial of coenzyme Q10 and GPI-1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment.
CC : 002B17; 002B17G
FD : Maladie de Parkinson; Pathologie du système nerveux; Croyance; Traitement; Erreur systématique; Essai clinique; Echelle d'évaluation
FG : Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED : Parkinson disease; Nervous system diseases; Belief; Treatment; Bias; Clinical trial; Evaluation scale
EG : Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD : Parkinson enfermedad; Sistema nervioso patología; Creencia; Tratamiento; Error sistemático; Ensayo clínico; Escala evaluación
LO : INIST-20953.354000170524820170
ID : 10-0314989

Links to Exploration step

Pascal:10-0314989

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Impact of Belief in Neuroprotection on Therapeutic Intervention in Parkinson's Disease</title>
<author>
<name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J." last="Elble">Rodger J. Elble</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Neurology, Southern Illinois University School of Medicine</s1>
<s2>Springfield, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Medical Genetics, University of Calgary</s1>
<s2>Calgary, Alberta</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Department of Clinical Neurosciences, University of Calgary</s1>
<s2>Calgary, Alberta</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation>
<inist:fA14 i1="04">
<s1>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina</s1>
<s2>Charleston, South Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name>
<affiliation>
<inist:fA14 i1="05">
<s1>Department of Neurology, University of Maryland School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Peng Huang" sort="Peng Huang" uniqKey="Peng Huang" last="Peng Huang">PENG HUANG</name>
<affiliation>
<inist:fA14 i1="06">
<s1>Department of Oncology, Johns Hopkins University</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name>
<affiliation>
<inist:fA14 i1="07">
<s1>Division of Biostatistics, University of Texas Health Science Center School of Public Health</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">10-0314989</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0314989 INIST</idno>
<idno type="RBID">Pascal:10-0314989</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A69</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Impact of Belief in Neuroprotection on Therapeutic Intervention in Parkinson's Disease</title>
<author>
<name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J." last="Elble">Rodger J. Elble</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Neurology, Southern Illinois University School of Medicine</s1>
<s2>Springfield, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Medical Genetics, University of Calgary</s1>
<s2>Calgary, Alberta</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Department of Clinical Neurosciences, University of Calgary</s1>
<s2>Calgary, Alberta</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation>
<inist:fA14 i1="04">
<s1>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina</s1>
<s2>Charleston, South Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name>
<affiliation>
<inist:fA14 i1="05">
<s1>Department of Neurology, University of Maryland School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Peng Huang" sort="Peng Huang" uniqKey="Peng Huang" last="Peng Huang">PENG HUANG</name>
<affiliation>
<inist:fA14 i1="06">
<s1>Department of Oncology, Johns Hopkins University</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name>
<affiliation>
<inist:fA14 i1="07">
<s1>Division of Biostatistics, University of Texas Health Science Center School of Public Health</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Belief</term>
<term>Bias</term>
<term>Clinical trial</term>
<term>Evaluation scale</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Croyance</term>
<term>Traitement</term>
<term>Erreur systématique</term>
<term>Essai clinique</term>
<term>Echelle d'évaluation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double-blind placebo-controlled futility trial of coenzyme Q
<sub>10</sub>
and GPI-1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0885-3185</s0>
</fA01>
<fA03 i2="1">
<s0>Mov. disord.</s0>
</fA03>
<fA05>
<s2>25</s2>
</fA05>
<fA06>
<s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Impact of Belief in Neuroprotection on Therapeutic Intervention in Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>ELBLE (Rodger J.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>SUCHOWERSKY (Oksana)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>SHAFTMAN (Stephanie)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>WEINER (William J.)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>PENG HUANG</s1>
</fA11>
<fA11 i1="06" i2="1">
<s1>TILLEY (Barbara)</s1>
</fA11>
<fA14 i1="01">
<s1>Department of Neurology, Southern Illinois University School of Medicine</s1>
<s2>Springfield, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Department of Medical Genetics, University of Calgary</s1>
<s2>Calgary, Alberta</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>Department of Clinical Neurosciences, University of Calgary</s1>
<s2>Calgary, Alberta</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04">
<s1>Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina</s1>
<s2>Charleston, South Carolina</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05">
<s1>Department of Neurology, University of Maryland School of Medicine</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="06">
<s1>Department of Oncology, Johns Hopkins University</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="07">
<s1>Division of Biostatistics, University of Texas Health Science Center School of Public Health</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1">
<s1>NINDS NET-PD Investigators</s1>
<s3>INC</s3>
</fA17>
<fA20>
<s1>1082-1086</s1>
</fA20>
<fA21>
<s1>2010</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>20953</s2>
<s5>354000170524820170</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>6 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>10-0314989</s0>
</fA47>
<fA60>
<s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Movement disorders</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double-blind placebo-controlled futility trial of coenzyme Q
<sub>10</sub>
and GPI-1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Pathologie du système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Croyance</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Belief</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Creencia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Traitement</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Treatment</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Tratamiento</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Erreur systématique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Bias</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Error sistemático</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Essai clinique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Clinical trial</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Ensayo clínico</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Echelle d'évaluation</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Evaluation scale</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Escala evaluación</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Pathologie du système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21>
<s1>200</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
<server>
<NO>PASCAL 10-0314989 INIST</NO>
<ET>Impact of Belief in Neuroprotection on Therapeutic Intervention in Parkinson's Disease</ET>
<AU>ELBLE (Rodger J.); SUCHOWERSKY (Oksana); SHAFTMAN (Stephanie); WEINER (William J.); PENG HUANG; TILLEY (Barbara)</AU>
<AF>Department of Neurology, Southern Illinois University School of Medicine/Springfield, Illinois/Etats-Unis (1 aut.); Department of Medical Genetics, University of Calgary/Calgary, Alberta/Canada (2 aut.); Department of Clinical Neurosciences, University of Calgary/Calgary, Alberta/Canada (3 aut.); Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina/Charleston, South Carolina/Etats-Unis (3 aut.); Department of Neurology, University of Maryland School of Medicine/Baltimore, Maryland/Etats-Unis (4 aut.); Department of Oncology, Johns Hopkins University/Baltimore, Maryland/Etats-Unis (5 aut.); Division of Biostatistics, University of Texas Health Science Center School of Public Health/Houston, Texas/Etats-Unis (6 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 8; Pp. 1082-1086; Bibl. 6 ref.</SO>
<LA>Anglais</LA>
<EA>We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double-blind placebo-controlled futility trial of coenzyme Q
<sub>10</sub>
and GPI-1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du système nerveux; Croyance; Traitement; Erreur systématique; Essai clinique; Echelle d'évaluation</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Belief; Treatment; Bias; Clinical trial; Evaluation scale</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Creencia; Tratamiento; Error sistemático; Ensayo clínico; Escala evaluación</SD>
<LO>INIST-20953.354000170524820170</LO>
<ID>10-0314989</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A69 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000A69 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0314989
   |texte=   Impact of Belief in Neuroprotection on Therapeutic Intervention in Parkinson's Disease
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024